Use of angiotensin receptor blockers and the risk of cancer

Circulation

Volumn 123, Issue 16, 2011, Pages 1729-1736

  Pasternak, Björn ^a   Svanström, Henrik ^a   Callréus, Torbjörn ^b   Melbye, Mads ^a   Hviid, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b DANISH MEDICINES AGENCY   (Denmark)

Author keywords

angiotensin II; epidemiology; neoplasms; postmarketing; product surveillance; safety

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; MOEXIPRIL; OLMESARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIAGNOSTIC PROCEDURE; DISEASE REGISTRY; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DENMARK; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; RISK FACTORS; UROGENITAL NEOPLASMS;

EID: 79955560688     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.007336     Document Type: Article

References (40)

1. Standards of medical care in diabetes: 2010. Diabetes Care. 2010; 33(suppl 1):S11-S61.
2. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-2016.
3. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, Kaplan NM, OConnor CM, OGara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-2788. (Pubitemid 46842793)
4. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensinreceptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627-636.
5. US Food and Drug Administration. Angiotensin receptor blockers (ARBs): ongoing safety review for cancer risk. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedical-Products/ucm219185.htm. Accessed July 15, 2010.
6. European Medicines Agency. Monthly report: Committee for Medicinal Products for Human Use (CHMP). http://www.ema.europa.eu/docs/en-GB/document- library/Committee-meeting-report/2010/07/WC500094208.pdf. Accessed July 2, 2010.
7. Coleman CI, Baker WL, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens. 2008; 26:622-629. (Pubitemid 351354904)
8. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, Olsen JH. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 2001;92: 2462-2470. (Pubitemid 33029093)
9. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352:179-184. (Pubitemid 28327802)
10. Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlof B, de Faire U, Forsen K, Hedner T, Linjer E, Schersten B, Wester P, Moller T. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients With Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet. 2001;358:539-544. (Pubitemid 32772729)
11. Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med. 2000;160:349-353. (Pubitemid 30075217)
12. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 2005;16:293-299. (Pubitemid 41206635)
13. Ino K, Shibata K, Kajiyama H, Nawa A, Nomura S, Kikkawa F. Manipulating the angiotensin system: new approaches to the treatment of solid tumours. Expert Opin Biol Ther. 2006;6:243-255. (Pubitemid 43344744)
14. Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Norgaard M, McLaughlin JK, Friis S. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat. 2006;97:231-236. (Pubitemid 43945753)
15. Koomen ER, Herings RM, Guchelaar HJ, Nijsten T. Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cancer Epidemiol. 2009;33:391-395.
16. Fryzek JP, Poulsen AH, Johnsen SP, McLaughlin JK, Sorensen HT, Friis S. A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer. 2005;92:1302-1306. (Pubitemid 40604409)
17. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System: a cohort of eight million persons. Dan Med Bull. 2006;53:441-449. (Pubitemid 44816920)
18. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Srensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106:86-94.
19. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920. (Pubitemid 37323253)
20. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry: history, content, quality and use. Dan Med Bull. 1997;44: 535-539.
21. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull. 1999;46:354-357. (Pubitemid 29439149)
22. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-268. (Pubitemid 29299976)
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383. (Pubitemid 17055592)
24. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139. (Pubitemid 41587600)
25. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncol. 2011;12: 65-82.
26. Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009;23:623-635.
27. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008;29:1675-1684.
28. Doi C, Egashira N, Kawabata A, Maurya DK, Ohta N, Uppalapati D, Ayuzawa R, Pickel L, Isayama Y, Troyer D, Takekoshi S, Tamura M. Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer. 2010;10:67.
29. Benndorf R, Boger RH, Ergun S, Steenpass A, Wieland T. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res. 2003;93:438-447. (Pubitemid 37100009)
30. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
31. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-offunction study using gene transfer. Proc Natl Acad Sci U S A. 1995;92: 10663-10667.
32. Clere N, Corre I, Faure S, Guihot AL, Vessieres E, Chalopin M, Morel A, Coqueret O, Hein L, Delneste Y, Paris F, Henrion D. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer. 2010;127:2279-2291.
33. Cozaar [losartan product information]. Whitehouse, NJ: Merck & Co; 2008. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020386s049lbl. pdf. Accessed June 23, 2010.
34. Diovan [valsartan product information]. East Hanover, NJ: Novartis; 2008. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/021283s027lbl.pdf. Accessed June 23, 2010.
35. Avapro [irbesartan product information]. New York, NY: Bristol-Myers Squibb Sanofi-Synthelabo; 2005. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2006/020757s038lbl.pdf. Accessed June 23, 2010.
36. Atacand [candesartan product information]. Wilmington, DE: Astra- Zeneca; 2009. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020838s031lbl. pdf. Accessed June 23, 2010.
37. Micardis [product information]. Ridgefield, CT: Boehringer Ingelheim; 2009. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020850s025lbl. pdf. Accessed June 23, 2010.
38. Benicar [olmesartan product information]. Parsippany, NJ: Daiichi Sankyo; 2009. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021286s018lbl. pdf. Accessed June 23, 2010.
39. Teveten [eprosartan product information]. Philadelphia, PA: SmithKline Beecham; 1998. http://www.accessdata.fda.gov/drugsatfda-docs/nda/98/20738S001- TEVETEN-PRNTLBL.PDF. Accessed June 23, 2010.
40. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19:858-868.